Location History:
- Gerrards Cross, Buckinghamshire, GB (1981)
- Pinner, GB (1989 - 1992)
- Stevenage, GB (2007)
Company Filing History:
3 out of 1,168 
2 out of 3,580 
1 out of 832,843 Years Active: 1981-2007
Title: Peter D Howes: A Pioneer in Anti-Viral Innovation
Introduction
Peter D Howes is a prolific inventor based in Pinner, GB, known for his significant contributions to the development of anti-viral agents. With a total of six patents to his name, he has been at the forefront of innovative solutions aimed at combating viral infections.
Latest Patents
Among his latest inventions are 1-acyl-pyrrolidine derivatives for the treatment of viral infections. These anti-viral agents are represented by a complex formula designed to optimize therapeutic effectiveness. The patent details specific structural requirements, indicating that A represents hydroxy, D can be aryl or heteroaryl, and E can be hydrogen, alkyl, aryl, or heterocyclyl. Additionally, the derivatives are designed for the treatment of Hepatitis C virus (HCV), making substantial contributions to pharmaceutical advancements. Another notable patent includes the development of 4-(6-membered)-heteroaryl acyl pyrrolidine derivatives as HCV inhibitors, which are novel anti-viral agents aimed at improving treatment outcomes.
Career Highlights
Peter’s career has included significant tenures in renowned pharmaceutical companies such as Glaxo Group Limited and American Cyanamid Company. These positions have provided him with valuable insights and resources to nurture his innovative projects, resulting in impactful patents and contributions to health sciences.
Collaborations
Throughout his career, Peter D Howes has worked alongside notable colleagues, including Derek R Sutherland and David Haigh. These collaborations have fostered an environment of innovation and knowledge sharing, further enhancing the development of his anti-viral inventions.
Conclusion
Peter D Howes stands out as an influential inventor in the field of virology, noted for his innovative approaches to developing anti-viral agents. His recent patents demonstrate a strong commitment to addressing viral infections, particularly HCV, and his collaborations with industry professionals indicate a robust network within the pharmaceutical sector. His work is paving the way for future breakthroughs in the treatment of viral diseases.